The overall response upon receiving EPO therapy (i.e., Hb increase greater than 20 g/L) was more than 70% and was observed both in primary and secondary wAIHA and CAD/CAS, as well in treatment-naïve patients and in relapsed/refractory patients previously treated with several treatment strategies. This evidence concerns the gene GSTM1 and cold agglutinin disease.